Prediction of human drug clearance from two species: A comparison of several allometric methods

Journal of Pharmaceutical Sciences

Volumn 99, Issue 3, 2010, Pages 1601-1613

  Goteti, Kosalaram ^a   Edwin Garner, C ^a   Mahmood, Iftekhar ^b  

^a ASTRAZENECA   (United Kingdom)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Clearance; Fixed exponents; Multiexponential allometry; Rule of exponents; Two species scaling

Indexed keywords

ACIVICIN; AMLOTRIPTAN; BICIFADINE; BOSENTAN; CARUMONEM; DOXAZOSIN; ENOXACIN; ERYTHROMYCIN; FASORACETAM; FELBAMATE; FENTANYL; GABAPENTIN; GRENEOXACIN; INDINAVIR; IRINOTECAN; LINEZOLID; METOPROLOL; MINAPRINE; MORPHINE; MOXIFLOXACIN; NISOLDIPINE; OFLOXACIN; PELRINONE; PHENAZONE; PROPRANOLOL; THEOPHYLLINE; TORCETRAPIB; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ACCURACY; ALLOMETRY; ARTICLE; DOG; DRUG CLEARANCE; FIXED EXPONENTS; HUMAN; MONKEY; MULTIEXPONENTIAL ALLOMETRY; NONHUMAN; RAT; RULE OF EXPONENTS; SIMPLE ALLOMETRY; SPECIES;

EID: 76649134798     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21926     Document Type: Article

References (85)

1. Mahmood I, Green MD, Fisher JE. 2003. Selection of the first-time dose in humans: Comparison of different approaches based on interspecies scaling of clearance. J Clin Pharmacol 43:692-697.
2. Mahmood I. 2005. Interspecies pharmacokinetic scaling. 1st edition. Rockville, MD: Pine House Publishers.
3. Mahmood I. 2009. Role of fixed coefficients and exponents in the prediction of human drug clearance: How accurate are the predictions from one or two species? J Pharm Sci 98:2472-2493.
4. Jolivette LJ, Ward KW. 2005. Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. J Pharm Sci 94:1467-1483.
5. Balani SK, Zhu T, Yang TJ, Liu Z, He B, Lee FW. 2002. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys. Drug Metab Dispos 30: 1059-1062.
6. Bachmann K. 1989. Predicting toxicokinetic parameters in humans from toxicokinetic data acquired from three small mammalian species. J Appl Toxicol 9:331-338.
7. Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo P. 1997. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs. J Pharm Sci 86:584-590.
8. Goteti K, Brassil PJ, Good SS, Garner CE. 2008. Estimation of human drug clearance using multiexponential techniques. J Clin Pharmacol 48:1226-1236.
9. Tang H, Hussain A, Leal M, Mayersohn M, Fluhler E. 2007. Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos 35:1886-1893.
10. Mahmood I, Balian JD. 1996. Interspecies scaling: Predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887-895.
11. Mahmood I. 2006. Prediction of drug clearance in children from adults: A comparison of several allometric methods. Br J Clin Pharmacol 61:545-557.
12. Mahmood I. 2009. Application of fixed exponent 0.75 to the prediction of human drug clearance: An inaccurate and misleading concept. Drug Metabol Drug Interact 24:57-81.
13. Mahmood I, Balian JD. 1996. Interspecies scaling: A comparative study for the prediction of clearance and volume using two or more than two species. Life Sci 59:579-585.
14. Lin JH, Chiba M, Balani SK, Chen IW, Kwei GY, Vastag KJ, Nishime JA. 1996. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 24:1111-1120.
15. Balani SK, Woolf EJ, Hoagland VL, Sturgill MG, Deutsch PJ, Yeh KC, Lin JH. 1996. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab Dispos 24: 1389-1394.
16. Rane A, Hogstedt S, Lindberg B, Regardh CG, Jorulf H. 1984. Comparison of different clearance estimates for metoprolol in the rhesus monkey. J Pharmacol Exp Ther 228:774-778.
17. Belpaire FM, de Smet F, Vynckier LJ, Vermeulen AM, Rosseel MT, Bogaert MG, Chauvelot-Moachon L. 1990. Effect of aging on the pharmacokinetics of atenolol, metoprolol and propranolol in the rat. J Pharmacol Exp Ther 254:116-122.
18. Murthy SS, Nelson WL, Shen DD, Power JM, Cahill CM, McLean AJ. 1991. Pharmacokinetic interaction between verapamil and metoprolol in the dog. Stereochemical aspects. Drug Metab Dispos 19: 1093-1100.
19. Kawakami J, Yamamoto K, Sawada Y, Iga T. 1994. Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data. J Pharmacokinet Biopharm 22:207-227.
20. Nakamura S, Kurobe N, Kashimoto S, Ohue T, Takase Y, Shimizu M. 1983. Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. Antimicrob Agents Chemother 24:54-60.
21. Somogyi AA, Bochner F. 1988. The absorption and disposition of enoxacin in healthy subjects. J Clin Pharmacol 28:707-713.
22. Siefert HM, Domdey-Bette A, Henninger K, Hucke F, Kohlsdorfer C, Stass HH. 1999. Pharmacokinetics of the 8-methoxyquinolone, moxi-floxacin: A comparison in humans and other mammalian species. J Antimicrob Chemother 43:69-76.
23. Hayakawa H, Fukushima Y, Kato H, Fukumoto H, Kadota T, Yamamoto H, Kuroiwa H, Nishigaki J, Tsuji A. 2003. Metabolism and disposition of novel des-fluoro quinolone garenoxacin in experimental animals and an interspecies scaling of pharmacokinetic parameters. Drug Metab Dispos 31:1409-1418.
24. Gajjar DA, Bello A, Ge Z, Christopher L, Grasela DM. 2003. Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob Agents Chemother 47:2256-2263.
25. Ubeaud G, Schmitt C, Jaeck D, Lave T, Coassolo P. 1995. Bosentan, a new endothelin receptor antagonist: Prediction of the systemic plasma clearance in man from combined in vivo and in vitro data. Xenobiotica 25:1381-1390.
26. McGovren JP, Williams MG, Stewart JC. 1988. Interspecies comparison of acivicin pharmacokinetics. Drug Metab Dispos 16:18-22.
27. Scatina JA, Hicks DR, Kraml M, Cayen MN. 1990. Metabolic disposition and pharmacokinetics of pelrinone, a new cardiotonic drug, in laboratory animals and man. Eur J Drug Metab Pharmacokinet 15:37-48.
28. Ahr HJ, Krause HP, Siefert HM, Suwelack D, Weber H. 1988. Pharmacokinetics of nisoldipine. I. Absorption, concentration in plasma, and excretion after single administration of [14C]nisoldipine in rats, dogs, monkey, and swine. Arzneimittelforschung 38:1093-1098.
29. Kirsten R, Nelson K, Kirsten D, Heintz B. 1998. Clinical pharmacokinetics of vasodilators. Part I. Clin Pharmacokinet 34:457-482.
30. Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, Sugiyama Y. 1996. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 277:1630-1641.
31. Loi CM, Young M, Randinitis E, Vassos A, Koup JR. 1999. Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 37:91-104.
32. Gascon AR, Calvo B, Hernandez RM, Dominguez-Gil A, Pedraz JL. 1994. Interspecies scaling of cimetidine-theophylline pharmacokinetic interaction: Interspecies scaling in pharmacokinetic interactions. Pharm Res 11:945-950.
33. Radulovic LL, Turck D, von Hodenberg A, Vollmer KO, McNally WP, DeHart PD, Hanson BJ, Bockbrader HN, Chang T. 1995. Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys. Drug Metab Dispos 23:441-448.
34. Bialer M. 1993. Comparative pharmacokinetics of the newer antiepileptic drugs. Clin Pharmacokinet 24:441-452.
35. Evans GH, Nies AS, Shand DG. 1973. The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J Pharmacol Exp Ther 186:114-122.
36. Davi H, Bonnet JM, Berger Y. 1992. Disposition of minaprine in animals and in human extensive and limited debrisoquine hydroxylators. Xenobiotica 22:171-184.
37. Milne RW, Nation RL, Somogyi AA. 1996. The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab Rev 28:345-472.
38. Bonati M, Latini R, Tognoni G, Young JF, Garattini S. 1984. Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat, and mouse. Drug Metab Rev 15:1355-1383.
39. Boothe DM, Cullen JM, Calvin JA, Jenkins WL, Brown SA, Green RA, Corrier DE. 1994. Antipyrine and caffeine dispositions in clinically normal dogs and dogs with progressive liver disease. Am J Vet Res 55:254-261.
40. Slatter JG, Adams LA, Bush EC, Chiba K, Daley-Yates PT, Feenstra KL, Koike S, Ozawa N, Peng GW, Sams JP, Schuette MR, Yamazaki S. 2002. Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica 32:907-924.
41. Stalker DJ, Jungbluth GL, Hopkins NK, Batts DH. 2003. Pharmacokinetics and tolerance of singleand multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 51:1239-1246.
42. Inaba M, Ohnishi Y, Ishii H, Tanioka Y, Yoshida Y, Sudoh K, Hakusui H, Mizuno N, Ito K, Sugiyama Y. 1998. Pharmacokinetics of CPT-11 in rhesus monkeys. Cancer Chemother Pharmacol 41:103-108.
43. Kaneda N, Yokokura T. 1990. Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 50:1721-1725.
44. Kaneda N, Nagata H, Furuta T, Yokokura T. 1990. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50:1715-1720.
45. Kita Y, Fugono T, Imada A. 1986. Comparative pharmacokinetics of carumonam and aztreonam in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother 29:127-134.
46. Berube D, Vallee F, Panneton AC, Bergeron MG, LeBel M. 1988. Pharmacokinetics of carumonam after single and multiple 1- and 2-g dosage regimens. Antimicrob Agents Chemother 32:354-357.
47. Howell SR, Hicks DR, Scatina JA, Sisenwine SF. 1994. Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals. Xenobiotica 24:315-327.
48. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST. 1992. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 32:716-724.
49. Mukai H, Sugimoto T, Ago M, Morino A. 1999. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: Absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105. Arzneimittelforschung 49:881-890.
50. Kumagai Y, Yokota S, Isawa S, Murasaki M, Mukai H, Miyatake S. 1999. Comparison of pharmacokinetics of NS-105, a novel agent for cerebrovascular disease, in elderly and young subjects. Int J Clin Pharmacol Res 19:1-8.
51. Jansat JM, Costa J, Salva P, Fernandez FJ, Martinez-Tobed A. 2002. Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. J Clin Pharmacol 42:1303-1310.
52. Aubets J, Cardenas A, Salva M, Jansat JM, Martinez-Tobed A, Palacios JM. 2006. Disposition and metabolism of almotriptan in rats, dogs and monkeys. Xenobiotica 36:807-823.
53. Prakash C, Chen W, Rossulek M, Johnson K, Zhang C, O'Connell T, Potchoiba M, Dalvie D. 2008. Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: Characterization of unusual and novel metabolites by highresolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance. Drug Metab Dispos 36:2064-2079.
54. Dalvie D, Chen W, Zhang C, Vaz AD, Smolarek TA, Cox LM, Lin J, Obach RS. 2008. Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans. Drug Metab Dispos 36:2185-2198.
55. Duthu GS. 1985. Interspecies correlation of the pharmacokinetics of erythromycin, oleandomycin, and tylosin. J Pharm Sci 74:943-946.
56. Valverde CR, Mama KR, Kollias-Baker C, Steffey EP, Baggot JD. 2000. Pharmacokinetics and cardiopulmonary effects of fentanyl in isofluraneanesthetized rhesus monkeys (Macaca mulatta). Am J Vet Res 61:931-934.
57. Bjorkman S, Redke F. 2000. Clearance of fentanyl, alfentanil, methohexitone, thiopentone and ketamine in relation to estimated hepatic blood flow in several animal species: Application to prediction of clearance in man. J Pharm Pharmacol 52:1065-1074.
58. Adusumalli VE, Yang JT, Wong KK, Kucharczyk N, Sofia RD. 1991. Felbamate pharmacokinetics in the rat, rabbit, and dog. Drug MetabDispos 19:1116-1125.
59. Krieter PA, Gohdes M, Musick TJ, Duncanson FP, Bridson WE. 2008. Pharmacokinetics, disposition, and metabolism of bicifadine in humans. Drug Metab Dispos 36:252-259.
60. Musick TJ, Gohdes M, Duffy A, Erickson DA, Krieter PA. 2008. Pharmacokinetics, disposition, and metabolism of bicifadine in the mouse, rat, and monkey. Drug Metab Dispos 36:241-251.
61. el Sayed MA, Loscher W, Frey HH. 1978. Pharmacokinetics of ethosuximide in the dog. Arch Int Pharmacodyn Ther 234:180-192.
62. Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL. 1986. The metabolism and kinetics of doxazosin in man, mouse, rat and dog. Br J Clin Pharmacol 21:19S-25S.
63. Hamilton CA, Reid JL, Vincent J. 1985. Pharmacokinetic and pharmacodynamic studies with two alpha-adrenoceptor antagonists, doxazosin and prazosin in the rabbit. Br J Pharmacol 86:79-87.
64. Haznedar JO, Patyna S, Bello CL, Peng GW, Speed W, Yu X, Zhang Q, Sukbuntherng J, Sweeny DJ, Antonian L, Wu EY. 2009. Single- and multipledose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: Comparative plasma kinetics in non-clinical species. Cancer Chemother Pharmacol 64:691-706.
65. Bello CL, Sherman L, Zhou J, Verkh L, Smeraglia J, Mount J, Klamerus KJ. 2006. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: Results from a phase I study in healthy subjects. Anticancer Drugs 17:353-358.
66. Kaul S, Dandekar KA, Schilling BE, Barbhaiya RH. 1999. Toxicokinetics of 2′,3′-didehydro-3′-deoxythymidine, stavudine (D4T). Drug Metab Dispos 27: 1-12.
67. Rana KZ, Dudley MN. 1997. Clinical pharmacokinetics of stavudine. Clin Pharmacokinet 33:276-284.
68. Cruze CA, Kelm GR, Meredith MP. 1995. Interspecies scaling of tebufelone pharmacokinetic data and application to preclinical toxicology. Pharm Res 12: 895-901.
69. Lave T, Saner A, Coassolo P, Brandt R, Schmitt-Hoffmann AH, Chou RC. 1996. Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor. J Pharm Pharmacol 48:573-577.
70. Sukbuntherng J, Cropp G, Hannah A, Wagner GS, Shawver LK, Antonian L. 2001. Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416. J Pharm Pharmacol 53:1629-1636.
71. Hildebrand M. 1994. Inter-species extrapolation of pharmacokinetic data of three prostacyclinmimetics. Prostaglandins 48:297-312.
72. Guentert TW, Huang JD, Oie S. 1982. Disposition of quinidine in the rabbit. J Pharm Sci 71:812-815.
73. Iven H. 1977. The pharmacokinetics and organ distribution of ajmaline and quindine in the mouse. Naunyn Schmiedebergs Arch Pharmacol 298:43-50.
74. Ueda CT, Ballard B, Rowland M. 1977. Concentration-time effects of quinidine disposition kinetics in rhesus monkeys. J Pharmacol Exp Ther 200:459-468.
75. Ramanathan-Girish S, McColm J, Clements JM, Taupin P, Barrowcliffe S, Hevizi J, Safrin S, Moore C, Patou G, Moser H, Gadd A, Hoch U, Jiang V, Lofland D, Johnson KW. 2004. Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor. Antimicrob Agents Chemother 48:4835-4842.
76. Doyle E, Chasseaud LF, Miller JN. 1982. Comparative pharmacokinetics of frusemide in female rhesus monkeys, cynomolgus monkeys and baboons. Comp Biochem Physiol C 71C: 89-93.
77. Hirai J, Miyazaki H, Taneike T. 1992. The pharmacokinetics and pharmacodynamics of furosemide in the anaesthetized dog. J Vet Pharmacol Ther 15: 231-239.
78. Prandota J, Pruitt AW. 1991. Pharmacokinetic, biliary excretion, and metabolic studies of 14C-furosemide in the rat. Xenobiotica 21:725-736.
79. Cook CS, Rozek LF, Stolzenbach J, Anderson S, Schoenhard GL, Karim A. 1993. Pharmacokinetics of a novel antiarrhythmic drug, actisomide. Pharm Res 10:427-433.
80. Ritschel WA, Vachharajani NN, Johnson RD, Hussain AS. 1991. Interspecies scaling of the pharmacokinetic parameters of coumarin among six different mammalian species. Methods Find Exp Clin Pharmacol 13:697-702.
81. Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, Hesney M, Winchell GA, Deutsch PJ, Greenberg H, Hunt TL, Waldman SA. 2002. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 46:739-745.
82. Hajdu R, Thompson R, Sundelof JG, Pelak BA, Bouffard FA, Dropinski JF, Kropp H. 1997. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 41:2339-2344.
83. Feng MR, Loo J, Wright J. 1998. Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome P450 2D6 extensive metabolizers. Species comparison and allometric scaling. Drug Metab Dispos 26:982-988.
84. Krause W, Schutt B, Duka T. 1990. Pharmacokinetics and acute toleration of the beta-carboline derivative abecarnil in man. Arzneimittelforschung 40:529-532.
85. Krause W, Mengel H. 1990. Pharmacokinetics of the anxiolytic beta-carboline derivative abecarnil in the mouse, rat, rabbit, dog, cynomolgus monkey and baboon. Studies on species differences. Arzneimittelforschung 40:522-529.